SC-43
Based on 6 publication(s) in Google Scholar
SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects.
For research use only. We do not sell to patients.
- Purity: 99.01%
- CAS No.: 1400989-25-4
- Formula: C21H13ClF3N3O2
- Molecular Weight:431.80
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) SC-43
More- Signal Transduct Target Ther. 2025 Apr 30;10(1):135. [Abstract]
- Cancer Commun (Lond). 2023 Apr;43(4):435-454. [Abstract]
- J Clin Invest. 2024 Oct 1;134(24):e183161. [Abstract]
- Int J Surg. 2026 Feb 12. [Abstract]
- J Pharm Biomed Anal. 2024 May 15:242:116023. [Abstract]
- bioRxiv. 2024 May 28:2024.05.23.595575. [Abstract]
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
-
ELISA
Biological Activity
|
SHP-1 |
p-STAT3 |
SC-43 (0-10 μM; 24-72 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment reveals the anti-proliferative effects in cholangiocarcinoma (CCA) cell lines in a dose-dependent manner after treating 24, 48 and 72 hours respectively[1].
SC-43 (0-10 μM; 24 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment shows increased sub-G1 cells and G2-M arrest, indicating SC-43 induced differential apoptotic effects in these cell lines[1].
SC-43 (0-10 μM; 24 hours; HuCCT-1, KKU-100, and CGCCA cells) treatment demonstrates significant increase in cleaved caspase-3 and PARP level[1].
SC-43 activates SH2 domain-containing phosphatase 1 (SHP-1) activity, leading to p-STAT3 and downstream cyclin B1 and Cdc2 downregulation. SC-43 augments SHP-1 activity by direct binding to N-SH2 and relief of its autoinhibition[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HuCCT-1, KKU-100, and CGCCA cells
-
Concentration:0 μM, 0.25 μM, 0.5 μM, 0.75 μM, 1 μM, 2.5 μM, 5 μM, 10 μM
-
Incubation Time:24 hours, 48 hours, 72 hours
-
Result:Revealed the anti-proliferative effects in CCA cell lines in a dose-dependent manner after treating 24, 48 and 72 hours respectively.
-
Cell Line:HuCCT-1, KKU-100, and CGCCA cells
-
Concentration:0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM
-
Incubation Time:24 hours
-
Result:Showed increased sub-G1 cells and G2-M arrest.
-
Cell Line:HuCCT-1, KKU-100, and CGCCA cells
-
Concentration:0 μM, 1 μM, 2.5 μM, 5 μM, 10 μM
-
Incubation Time:24 hours
-
Result:Demonstrated significant increase in cleaved caspase-3 and PARP level.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male NCr athymic nude mice (5-7 weeks of age) injected with HuCCT-1 cells[1]
-
Dosage:10 mg/kg or 30 mg/kg
-
Administration:Oral gavage; daily; for 23 days
-
Result:Exhibited xenograft tumor growth inhibition, p-STAT3 reduction and SHP-1 activity elevation.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1400989-25-4
-
Appearance Solid
-
Molecular Weight 431.80
-
Formula C21H13ClF3N3O2
-
Color White to off-white
-
SMILES
O=C(NC1=CC=CC(OC2=CC=C(C#N)C=C2)=C1)NC3=CC=C(Cl)C(C(F)(F)F)=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Branched-chain amino acids alleviate sepsis-induced myocardial dysfunction via inhibition of protein tyrosine phosphatase-6. [Abstract]2025 Apr 30;10(1):135. PMID: 40301312 -
Cancer Commun (Lond)
Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer. [Abstract]2023 Apr;43(4):435-454. PMID: 36855844 -
J Clin Invest
Neutrophil-specific Shp1 loss results in lethal pulmonary hemorrhage in mouse models of acute lung injury. [Abstract]2024 Oct 1;134(24):e183161. PMID: 39352872
SC-43 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Oct 1;134(24):e183161. [Abstract]
SC-43 (10 mg/kg; oral gavage; three intermittent doses before and after LPS administration) treatment reduced alveolar neutrophils and CitH3-DNA NET complexes, while alveolar protein leakage and NE-DNA NET levels were unchanged..
SC-43 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Oct 1;134(24):e183161. [Abstract]
Lung H&E stained tissue in DMSO control and SC43 (SC-43) (10 mg/kg; oral gavage; three intermittent doses before and after LPS administration) treated mice indicating reduced perihilar inflammation with SC43 administration.
SC-43 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Oct 1;134(24):e183161. [Abstract]
Dose-dependent reduction in LPS-induced ROS (superoxide release) production with SC43 (SC-43) (10 mg/kg; oral gavage; three intermittent doses before and after LPS administration) versus DMSO (vehicle) control (n = 3).
-
Int J Surg
Inhibition of Sirpα expression enhances microglial phagocytic clearance of myelin debris and reduces neuronal PANoptosis after spinal cord injury. [Abstract]2026 Feb 12. PMID: 41677350 -
J Pharm Biomed Anal
Impacts of small-molecule STAT3 inhibitor SC-43 on toxicity, global proteomics and metabolomics of HepG2 cells. [Abstract]2024 May 15:242:116023. PMID: 38395000
SC-43 purchased from MedChemExpress. Usage Cited in: J Pharm Biomed Anal. 2024 May 15:242:116023. [Abstract]
Effect of SC-43 with various concentrations on the cell viability at various time points. Cells were treated with SC-43 (0.78-100 μM) at various concentrations for 2 h、4 h、8 h、12 h and 24 h. Cell viability was determined by the Cell Counting Kit-8.
SC-43 purchased from MedChemExpress. Usage Cited in: J Pharm Biomed Anal. 2024 May 15:242:116023. [Abstract]
Effect of SC-43 with different concentrations on the RPA1 and TAP1 protein levels in HepG2 cells. Cells were treated with SC-43 (3.125-25 μM) at various concentrations for 2 h. The protein level was determined by the ELISA kit.
-
bioRxiv
2024 May 28:2024.05.23.595575. PMID: 38854059
Solvent & Solubility
DMSO : 250 mg/mL (578.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (4.82 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ming-Hung Hu, et al. Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget. 2017 May 10;8(39):65077-65089. [Content Brief]
[2]. Tung-Hung Su, et al. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. Sci Rep. 2017 May 11;7(1):1728. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3159 mL | 11.5794 mL | 23.1589 mL | 57.8972 mL |
| 5 mM | 0.4632 mL | 2.3159 mL | 4.6318 mL | 11.5794 mL | |
| 10 mM | 0.2316 mL | 1.1579 mL | 2.3159 mL | 5.7897 mL | |
| 15 mM | 0.1544 mL | 0.7720 mL | 1.5439 mL | 3.8598 mL | |
| 20 mM | 0.1158 mL | 0.5790 mL | 1.1579 mL | 2.8949 mL | |
| 25 mM | 0.0926 mL | 0.4632 mL | 0.9264 mL | 2.3159 mL | |
| 30 mM | 0.0772 mL | 0.3860 mL | 0.7720 mL | 1.9299 mL | |
| 40 mM | 0.0579 mL | 0.2895 mL | 0.5790 mL | 1.4474 mL | |
| 50 mM | 0.0463 mL | 0.2316 mL | 0.4632 mL | 1.1579 mL | |
| 60 mM | 0.0386 mL | 0.1930 mL | 0.3860 mL | 0.9650 mL | |
| 80 mM | 0.0289 mL | 0.1447 mL | 0.2895 mL | 0.7237 mL | |
| 100 mM | 0.0232 mL | 0.1158 mL | 0.2316 mL | 0.5790 mL |